Ranitidine bismuth citrate was compared with an equipotent dose of ranitidine, to determine whether the former, by an anti-Helicobacter pylon activity, would counteract the rise of gastrin resulting from ranitidine's gastric acid antisecretory activity. Twenty four men with duodenal ulcers were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily or ranitidine 300 mg twice daily (double blind, randomised, parallel groups). Fasting and postprandial plasma gastrin and plasma pepsinogen I and II concentrations were measured, and a "C-urea breath test was perforned before and on the 8th day of dosing. The "C-urea breath tests were positive in 21 patients before dosing and remained positive in nine of nine of the ranitidine dosed patients, whereas only two of 12 patients treated with ranitidine bismuth citrate remained positive. The expected rise in meal stimulated plasma gastrin with ranitidine was seen in the 12 patients who received ranitidine but, despite suppression of H pylon urease activity in 10 of 12 patients taking ranitidine bismuth citrate, there was no attenuation of the meal stimulated gastrin rise. There was no significant difference in the mean derived (4 hour) plasma pepsinogen I and II concentrations after dosing with ranitidine or ranitidine bismuth citrate.
Ranitidine bismuth citrate is a bismuth compound with gastric acid antisecretory activity'; the drug is formed by reacting ranitidine with bismuth citrate. Treatment with H2 receptor antagonists at conventional doses results in a modest increase in the plasma gastrin concentration; for example, dosing with ranitidine 300 mg at night resulted in a 58% increase in the 24 hour integrated plasma gastrin concentration on the 7th day of dosing.2 Higher doses cause a greater increase in the 24 hour plasma gastrin concentration inversely proportional to the antisecretory effect; for example, on the 7th day of dosing with ranitidine 300 mg twice daily, the 24 hour plasma gastrin concentration increased by 165% compared with baseline.' Ranitidine bismuth citrate is being developed, among other indications, for the treatment of duodenal ulcer patients most of whom have Helicobacter pylorn in their gastric mucosa.' H pylon' infection is associated with a reversible increase in the 24 hour plasma gastrin concentration5 and plasma pepsinogen I (PG I) and pepsinogen II (PG II) concentration.67 The postprandial plasma gastrin response and the raised PG I and PG II concentrations are reduced by eradication of H pylori.72 Most bismuth compounds have significant inhibitory effects on H pylori, although eradication is uncommon after dosing with bismuth alone." The object of the present study was to compare the effect of dosing with either ranitidine, or ranitidine bismuth citrate, on postprandial gastrin and pepsinogen release in H pylon infected duodenal ulcer patients.
Methods
Twenty four men with a history of H pylon' positive duodenal ulceration, confirmed by endoscopy and antral biopsy specimens in the preceding four years were studied. Patients with other significant diseases or with a history of alcohol abuse were excluded. Patients who had received a bismuth compound within the past 3 months or an antisecretory drug within 2 weeks before the study were also excluded.
The patients were investigated using a randomised, double blind parallel group design; they were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily (GR 12231 IX: Glaxo Group Research Ltd, Ware, UK), or ranitidine 300 mg twice daily (as ranitidine hydrochloride; Glaxo Group Research Ltd). Ranitidine bismuth citrate 800 mg contains the equivalent of ranitidine 300 mg as the hydrochloride. On each study morning, the fasting patients had a baseline blood sample of 0800 hours, followed by a standard breakfast at 0815 hours; hourly blood samples were taken until 1200 hours. The blood samples were centrifuged immediately and two plasma samples were stored at -20°C for each time interval. The plasma gastrin concentration was analysed at Royal Postgraduate Medical School (Professor Bloom's laboratory) by radioimmunoassay.'4 Duplicate samples were coded and shipped in dry ice to Los Angeles where they were analysed for PG I and PG II by radioimmunoassay. "5 At 1200 hours, a "C-urea breath test was performed by a standard protocol.'6"7 Briefly, a baseline breath sample was taken, and the patient given 100 mg of '"C-urea 10 minutes after a high fat liquid meal (100 ml). Exhaled breath samples were pooled in a large bag at 5 minute intervals from 10 to 40 minutes after giving the '3C-urea. The ratio of "CO2 to '2CO2 in the baseline and post "C-urea expired air samples were measured by mass spectrometry with cryogenic extraction of the CO2, using a dual inlet ratio mass spectrometer (BSIA, Brentford, Middlesex). The results for excess "CO2 are expressed as parts/ eighth day of dosing with ranitidine bismuth Excess 13C02 (per mil) citrate (Fig 3) . Since this was a randomised,
The correlation between the excess "CO, before dosing and the derived 4 hour plasma double blind study the disparity at baseline is oncentration in 23 duodenal ulcerpatients (r=064, p=0 001). more poorly absorbed bismuth compounds such as bismuth subsalicylate, suggests that systemic absorption is not required. 8 There was no significant change in the H pylori urease activity after dosing with ranitidine 300 mg twice daily for 7 days. Dosing with ranitidine resulted in the expected increase in the postprandial plasma gastrin concentration, which is consistent with, and inversely correlated to, its antisecretory activity.' There was no significant change in the plasma PG I or PG II concentration after 7 days of dosing with ranitidine. The expected ablation of the meal stimulated increase in plasma gastrin was not observed after dosing with ranitidine bismuth citrate. The "Curea breath test is reproducible and provides an 33 The mechanism of this increase is also unknown; gastritis and backdiffusion of the zymogens or a direct stimulation of secretion by a bacterial product of H pylon are possible explanations.34 35 The time required for the resolution of plasma gastrin to normal and the reduction of plasma pepsinogens after eradication is uncertain. The plasma gastrin and pepsinogen concentrations were significantly reduced 6 weeks after complete eradication of H pylori in a study of asymptomatic H pylori infected subjects" 12 and 4 weeks after completing treatment in a study of duodenal ulcer patients,36 but had not changed 24 hours after beginning eradication treatment in another study of duodenal ulcer patients. 29 More prolonged dosing with ranitidine or ranitidine bismuth citrate might have resulted in significant differences in the postprandial plasma gastrin and plasma pepsinogen concentrations. 
